OTIXAL 0.3 % — DIN 02459655
CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % FLUOCINOLONE ACETONIDE : 0.025 % · MEDEXUS PHARMACEUTICALS INC. · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OTIXAL?
OTIXAL 0.3 % contains CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % FLUOCINOLONE ACETONIDE : 0.025 %. It is listed in the Health Canada Drug Product Database under DIN 02459655, held by MEDEXUS PHARMACEUTICALS INC., supplied as SOLUTION for OTIC administration. Health Canada currently lists it as marketed, status dated 25-Jan-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OTIXAL used for?
OTIXAL (0.3% w/v ciprofloxacin (as ciprofloxacin hydrochloride) and 0.025% w/v fluocinolone acetonide) otic solution is indicated for the treatment of acute otitis media with tympanostomy tubes (AOMT) in pediatric patients (age 6 months and older) due to Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis and Pseudomonas aeruginosa. To reduce the development of drug-resistant bacteria and maintain the effectiveness of OTIXAL and other antibacterial drugs, OTIXAL should be used only to treat infections that are proven or strongly suspected to be caused by bacteria.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Fluocinolone Acetonide And Antiinfectives in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Fluocinolone Acetonide And Antiinfectives, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| MEDEXUS PHARMACEUTICALS INC. | 1 | 1 | OTIXAL | Sourceable in Canada |
| MEDICIS CANADA LTD. | 1 | 0 | SYNALAR BI-OTIC SOLUTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.3 % |
|---|---|
| Dosage form | SOLUTION |
| Route | OTIC |
| Pack configuration (monograph) | Two vials are packed per pouch (sample). Fifteen vials, divided in three strips of five vials, are packed per pouch (commercial pack). Forty-eight vials divided into twenty-four pouches, strips of two vials per pouch (commercial pack). |
| Storage | Store at room temperature (15°C to 30°C). Protect from light; store unused vials in pouch and discard 7 days after opening the pouch. Do not open until ready to use. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Fluocinolone Acetonide And Antiinfectives |
|---|---|
| ATC code | S02CA05 |
| AHFS class | 92:20.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02459655 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2459655 |
| Brand name | OTIXAL |
| Generic / active ingredient | CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) : 0.3 % FLUOCINOLONE ACETONIDE : 0.025 % |
| Market authorization holder | MEDEXUS PHARMACEUTICALS INC. |
| Health Canada schedule | Prescription |
| ATC code | S02CA05 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S02CA |
| Current status | MARKETED |
| Status date | 25-Jan-2023 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SYNALAR BI-OTIC SOLUTION | 3.5 MG | SOLUTION | MEDICIS CANADA LTD. | CANCELLED POST MARKET | 00189499 |
2 · Same class — other molecules in ATC S02CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Dexamethasone And Antiinfectives | CIPRODEX · SANDOZ CIPROFLOXACIN / DEXAMETHASONE · TARO-CIPROFLOXACIN/DEXAMETHASONE | 3 | 3 | Yes |
| Flumetasone And Antiinfectives | LOCACORTEN VIOFORM EARDROPS · PMS-FLUMETHASONE-CLIOQUINOL | 2 | 1 | Yes |
| Fluocinolone Acetonide And Antiinfectives | OTIXAL · SYNALAR BI-OTIC SOLUTION | 2 | 1 | Yes |
| Hydrocortisone And Antiinfectives | CIPRO HC OTIC SUSPENSION · CORTISPORIN · ODAN-SPOR-HC · OTIZOL HC LIQ · +2 more | 6 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.